Published online Feb 15, 2015. doi: 10.4239/wjd.v6.i1.30
Peer-review started: July 19, 2014
First decision: October 29, 2014
Revised: October 31, 2014
Accepted: November 27, 2014
Article in press: December 1, 2014
Published online: February 15, 2015
Core tip: The use of sulfonylurea is significantly associated with severe hypoglycemia in patients with type 2 diabetes. Biguanide and thiazolidinediones use are also highly associated with severe hypoglycemia. The intensified insulin therapy is more frequently associated with severe hypoglycemia compared with other insulin therapies. Low socioeconomic status, aging, longer duration of diabetes, high HbA1c and low body mass index, comorbidities, poor cognitive and mental function are precipitating factors for severe hypoglycemia.